Gilead JAKs up oncology presence with $510m YM buy
This article was originally published in Scrip
Executive Summary
YM BioSciences surged 76.7% to close at $2.88 per share on 12 December after Gilead Sciences said it would pay $2.95 per share to buy YM and expand its oncology pipeline, valuing the Canadian developer of the selective janus kinase (JAK) 1 and 2 inhibitor CYT387 at US$510 million.
You may also be interested in...
Finance Watch: Rakuten Aspyrian Raises $150m VC Round For Laser-Activated Cancer Drugs
Private investors, including Japanese e-commerce mogul Hiroshi Mikitani, backed a $150m Series C round for Rakuten Aspyrian and its photoimmunotherapy platform. Also, pharma-backed therapeutic video game developer Akili boosts Series C to $68m, and Summit garners additional BARDA funding.
Gilead's Late-Stage R&D Misfire Gives Respite To Competing Myelofibrosis Therapies
The JAK inhibitor momelotinib meets some endpoints but misses others in two late-stage clinical studies in myelofibrosis, a condition that has proved recalcitrant to various new approaches, leaving Incyte/Novartis’s marketed product ruxolitinib as one of the few successes.
Finance Watch: Have Investors Reached IPO Fatigue?
Public Company Edition: Codiak, Kiromic, Aligos and Opthea have fallen below their initial public offering values, while Tarsus and Praxis are trading higher. Also, 5AM, MPM and Cormorant took biotech SPACs public and Evotec led recent non-IPO financings with a €250m private placement.
Need a specific report? 1000+ reports available
Buy Reports